AIG
ACRV icon

American International Group’s Acrivon Therapeutics ACRV Stock Holding History

American International Group’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,016
Closed -$43K – 39
2024
Q1 		$43K Buy
6,016
+1,695
+39% +$7.87K ﹤0.01% 2818
2023
Q4 		$21.3K Sell
4,321
-17
-0.4% -$90 ﹤0.01% 2957
2023
Q3 		$41.5K Buy
4,338
+155
+4% +$1.79K ﹤0.01% 2863
2023
Q2 		$54.2K Buy
4,183
+5
+0.1% +$61 ﹤0.01% 2862
2023
Q1 		$53K Buy
+4,178
New +$70.2K ﹤0.01% 2692

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American International Group's ACRV Position: Q2 2024 in Review

American International Group sold out of Acrivon Therapeutics (ACRV) in Q2 2024, closing a stake of 6,016 shares — an estimated $43K sold.

American International Group first reported a position in ACRV in Q1 2023 and held it in 5 quarters. The position peaked at $54.2K in Q2 2023. 55 funds tracked by Wall St. Rank hold ACRV as of Q2 2024.

  • American International Group reported no remaining Acrivon Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 6,016 Acrivon Therapeutics shares in Q2 2024, an estimated $43K.
  • American International Group first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 5 quarters.
  • American International Group's Acrivon Therapeutics position peaked at $54.2K in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.